Leesha Ellis Cox, MD
Psychiatry · Birmingham, ALNPI 1598764698
Payments from drug & device makers
Across 1,671 payments — averaging $390.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$379K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$219K
- E.r. Squibb & Sons, L.L.C.$39K
- Teva Pharmaceuticals USA, Inc.$5K
- Otsuka America Pharmaceutical, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- plus $8K from 17 others
What the payments were for
- Consulting fees$45,1807%
- Speaking & faculty fees$513,83679%
- Travel & lodging$61,7359%
- Food & beverage$31,9255%
- Education$5180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 477 | $378,952 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 340 | $219,005 |
| E.r. Squibb & Sons, L.L.C. | 76 | $38,656 |
| Teva Pharmaceuticals USA, Inc. | 102 | $4,809 |
| Otsuka America Pharmaceutical, Inc. | 157 | $2,415 |
| Neurocrine Biosciences, Inc. | 86 | $1,688 |
| Vanda Pharmaceuticals Inc. | 62 | $1,446 |
| Johnson & Johnson | 56 | $1,217 |
| Lundbeck LLC | 54 | $1,117 |
| Ironshore Pharmaceuticals Inc. | 66 | $971 |
| AbbVie | 71 | $838 |
| Indivior Inc. | 49 | $651 |
| Axsome Therapeutics, Inc. | 20 | $386 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $368 |
| Supernus Pharmaceuticals, Inc. | 7 | $209 |
| Sunovion Pharmaceuticals Inc. | 19 | $209 |
| Tris Pharma Inc | 4 | $91 |
| Biogen | 1 | $75 |
| Collegium Pharmaceutical, Inc. | 2 | $31 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
| Shire North American Group Inc | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$927,688
- ARISTADA$576,996
- CAPLYTA$214,191
- ARISTADA INITIO$125,235
- COBENFY$29,687
- ABILIFY MAINTENA$249
- INGREZZA$244
- JORNAY PM$125
- ABILIFY ASIMTUFII$125
How this compares
$653,195 in reported general payments places this provider in the 95th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 88 | $258,801 |
| Austedo XrDeutetrabenazine | 17 | $187,690 |
| AustedoDeutetrabenazine | 12 | $183,471 |
| Abilify MaintenaAripiprazole | 57 | $165,549 |
| AristadaAripiprazole Lauroxil | 38 | $118,687 |
| CaplytaLumateperone Tosylate | 31 | $51,832 |
| RexultiBrexpiprazole | 29 | $51,779 |
| PerserisRisperidone | 14 | $32,960 |
| VraylarCariprazine Hcl | 24 | $25,586 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $20,696 |
| Aripiprazole | 56 | $5,696 |
| Asenapine Maleate | 21 | $4,518 |
| Haloperidol Decanoate | 52 | $3,427 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $3,168 |
| Divalproex Sodium | 104 | $3,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $4,809 | $371,16129 claims |
| Johnson & JohnsonInvega Sustenna | $1,217 | $258,80188 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $2,415 | $217,32886 claims |
| Alkermes, Inc.Aristada, Lybalvi | $378,952 | $139,38352 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $219,005 | $51,83231 claims |
| Indivior Inc.Perseris | $651 | $32,96014 claims |
| AbbVieVraylar | $838 | $25,58624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Birmingham
- Matthew MacalusoBirmingham$2.8M
- Richard SheltonBirmingham$2.4M
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Godehard OepenBirmingham$516K
- Melissa KarrhBirmingham$51K
- Santosh PillaiBirmingham$39K
- Jennifer HadleyBirmingham$27K
- Kerry ClearyBirmingham$12K
- Praveen JettyBirmingham$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.